Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
504 - Dear PAAB Can the branding of disease specific information for medical professionals resemble the branding of a product not yet launched? (i.e. Does PAAB place any restrictions on the branding of disease specific information and product APS?)
-
This is a Food and Drug Regulations issue. You may want to get some background from your legal department. Promotion of a product (whether direct or indirect) which is not approved in Canada would contravene section C.08.002 of the Food and Drug Regulations. It therefore follows that Canadian materials (even if only comprised of disease information) should not utilize branding from other jurisdictions in which the sponsor’s product was approved. Keep in mind that healthcare professionals may have seen these branding elements online and/or at international conferences.
-
@Jennifer-Carroll Thank you for sharing this information.
